英格兰结节性痒疹的患病率、发病率及治疗模式:回顾性数据库分析
本研究基于英格兰临床实践研究数据链和医院统计数据库,纳入2007年4月1日至2019年3月1日期间首次诊断结节性痒疹(PN)的成人患者8933例,其中中重度PN(MSPN)2498例、轻度PN(MiPN)6435例,并按年龄、性别和索引诊断日期1:1匹配各2462例进行比较。结果显示研究期间PN总体患病率和发病率均呈上升趋势,MSPN患者中特应性皮炎、哮喘和嗜酸性食管炎比例显著更高(均P<0.001),且强效/超强效外用糖皮质激素及多种系统药物的处方率显著高于MiPN(均P<0.001)。
要点
- 研究期间英格兰PN总体患病率和发病率均呈上升趋势。
- MSPN患者特应性皮炎、哮喘和嗜酸性食管炎比例显著高于MiPN(均P<0.001)。
- MSPN患者强效外用糖皮质激素及系统药物处方率显著高于MiPN(均P<0.001)。
核心结论
- 英格兰PN流行病学特征与其他欧洲研究一致,研究期间PN患病率和发病率均上升。
- MSPN患者强效外用糖皮质激素和系统药物的处方数显著多于MiPN患者。
- 中重度PN可能需要新的已获批治疗选择。
研究设计与样本
- 回顾性队列研究,使用英格兰临床实践研究数据链和医院统计数据库。
- 纳入2007年4月1日至2019年3月1日期间首次记录PN诊断码的成人患者(≥18岁),要求索引诊断日期前6个月及后≥12个月有可用数据。
- 根据索引诊断后是否处方系统免疫抑制剂或加巴喷丁类药物将患者分为MSPN和MiPN,并按年龄、性别和索引诊断日期1:1匹配。
主要发现
- 共纳入8933例患者(MSPN 2498例,MiPN 6435例),匹配比较分析各纳入2462例。
- MSPN患者中特应性皮炎、哮喘和嗜酸性食管炎比例显著高于MiPN(均P<0.001)。
- 研究期间PN总体患病率上升,发病率呈相似趋势。
- MSPN患者强效和超强效外用糖皮质激素、外用钙调神经磷酸酶抑制剂、第一代和第二代抗组胺药、口服和注射系统糖皮质激素、甲氨蝶呤、抗抑郁药和他克莫司的处方率显著高于MiPN(均P<0.001)。
临床怎么用
- 在英格兰,PN患者数量呈增加趋势,中重度患者常接受未获批用于该病的药物治疗。
- 临床需关注PN患者伴发的特应性皮炎、哮喘和嗜酸性食管炎等疾病。
- 中重度PN的治疗需求提示可能需要新的已获批治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England. OBJECTIVES: To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England. METHODS: This retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged ≥ 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and ≥ 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed. RESULTS: A total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P < 0.001) in patients with MSPN compared with those with MiPN. CONCLUSIONS: The epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN. Prurigo nodularis is an itchy skin disease that can affect a person’s daily life and sleep, and is often accompanied by other diseases. Skin ointments are used to treat the disease. If these are not effective, the disease is treated with oral medicine. The severity of prurigo nodularis is not well established. People with prurigo nodularis and treated with skin ointments are generally considered to have a milder form of the disease. Patients with severe disease most often require oral medicine that target the immune system. In England, there are no estimates of how often prurigo nodularis has affected the population over the last 10 years. In this study, we looked at cases of mild and moderate-to-severe prurigo nodularis in England and the treatments used by patients. We found that cases of prurigo nodularis (both mild and moderate-to-severe) increased during the study period, which was 2007 to 2019. Patients with the more severe form of the disease were more often treated with drugs that were not approved for treating it. Overall, our findings suggest that the number of patients with prurigo nodularis is increasing in England. A new and approved treatment option might be required to manage moderate-to-severe disease.
引用
- Bahloul D, Hudson R, Balogh O, et al. Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol. 2024. PMID: 38832950. doi:10.1093/bjd/ljae207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。